Advances in the management of hyperlipidemia-induced atherosclerosis.

Abstract

Although hyperlipidemia clearly plays a role in developing cardiovascular disease, the 10% of the population with the highest LDL levels account for only 20% of cardiovascular disease events. Thus, in order to significantly reduce the burden of cardiovascular disease, subjects with only modest dyslipidemia need to be treated with lipid-lowering therapy. Current guidelines have recommended aggressive lipid-lowering therapy in subjects at high risk of cardiovascular disease. The rationale behind this and treatment options to achieve target lipid goals are discussed.

• Authors: Lisa R Tannock
• Journal: Expert review of cardiovascular therapy (Expert Rev Cardiovasc Ther) Vol. 6 Issue 3 Pg. 369-83 (Mar 2008) ISSN: 1744-8344 [Electronic] England
• PMID: 18327996 (Publication Type: Journal Article, Review)

Chemical References

• Anticholesteremic Agents
• Cholesterol, HDL
• Cholesterol, LDL

Topics

• Anticholesteremic Agents (adverse effects, therapeutic use)
• Atherosclerosis (etiology, mortality, physiopathology)
• Cardiovascular Diseases (etiology, prevention & control)
• Cholesterol, HDL (blood)
• Cholesterol, LDL (blood)
• Dose-Response Relationship, Drug
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Humans
• Hyperlipidemias (complications, diagnosis, drug therapy, mortality)
• Male
• Practice Guidelines as Topic
• Risk Assessment
• Severity of Illness Index
• Survival Rate
• Treatment Outcome